SciSparc Ltd. (SPRC) Announces Japanese Patent Application for Novel Pain Management Combination
Tel Aviv, Israel – May 27, 2025 – In a move that could reshape the landscape of pain management, clinical-stage pharmaceutical company SciSparc Ltd. (Nasdaq: SPRC) revealed today the publication of a Japanese divisional patent application. This marks a pivotal step in the development of a potentially safer and more effective treatment approach for a widespread ailment.
The patent centers on a groundbreaking pharmaceutical combination: paracetamol, a common pain reliever, and palmitoylethanolamide (PEA). The innovative formulation aims to provide superior pain and fever relief, potentially utilizing lower doses compared to traditional paracetamol-based treatments. This could translate to a considerable reduction, on the health front, for many patients.
This strategic combination leverages PEA’s ability to boost the body’s endocannabinoid system. The implications could be far-reaching. This synergistic approach could potentially mitigate the risk of liver damage often associated with paracetamol use. Simultaneously, it could significantly improve therapeutic outcomes for a range of conditions, including acute, chronic, and neuropathic pain, as well as fever management.
“This patent represents a significant innovation in pain management,” stated Oz Adler, Chief Executive Officer of SciSparc. “This drug candidate combines paracetamol, a widely used pain reliever and fever reducer, with PEA, a natural compound that boosts the body’s endocannabinoid system. By working synergistically, the combination may reduce the required paracetamol dose, minimizing risks like liver damage while improving outcomes for acute, chronic, and neuropathic pain, as well as fever.”
The patent application suggests several positive trajectories:
* Improved safety profiles for pain management treatments.
* Reduced side effects when compared to standard treatments.
* The possibility of superior pain and fever relief through the synergistic effects of the combined drugs.
* A strong entry into a global market.
It is important to note that the patent is still in its application phase and that results are yet to be quantified through clinical trials.
**FAQ**
* What is the new patent application from SciSparc (SPRC) about?
SciSparc’s Japanese patent application covers a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA) designed to enhance pain and fever relief with lower doses and fewer side effects compared to traditional paracetamol treatments.
* How does SciSparc’s (SPRC) new drug combination work?
The combination works by combining paracetamol with PEA, which boosts the body’s endocannabinoid system. This synergistic approach aims to reduce required paracetamol dosage while improving pain relief effectiveness and minimizing side effects.
* What are the potential benefits of SciSparc’s (SPRC) new pain management patent?
The potential benefits include enhanced pain and fever relief, reduced risk of liver damage due to lower paracetamol doses, fewer side effects, and improved treatment outcomes for acute, chronic, and neuropathic pain.
* Where has SciSparc (SPRC) filed the patent for its new pain management drug?
SciSparc has filed a divisional patent application in Japan for its novel paracetamol and PEA combination therapy.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/1046.html
